Citius Oncology reports 120% shipment growth for Citius Pharmaceuticals stock

Published on 10/28/2026 at 05:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LYMPHIR shipments reached 792 units in fiscal Q4 2026, up from 360. Citius Pharmaceuticals stock awaits full results due in December 2026.

Commercial milestones and reporting date

Preliminary LYMPHIR shipments reached 792 units in the fiscal fourth quarter ended September 30, 2026, versus 360 units previously.
On October 26, 2026, 54 institutions had ordered LYMPHIR, compared with 44 on August 14, 2026.
TradingView lists December 17, 2026, as the next Citius Pharmaceuticals earnings date.

CTXR, US17322U3068, Illustration mit AI erstellt.

Citius Pharmaceuticals (ISIN US17322U3068) is tied to preliminary fiscal fourth-quarter LYMPHIR shipments of 792 units, versus 360 in the preceding quarter. The figures were released on October 26, 2026, by its majority-owned subsidiary Citius Oncology in a preliminary update covered by Citius Oncology.

Shipments doubled in fiscal Q4

Wholesale purchases more than doubled on the reported comparison, rising 120 percent from 360 units in the three months ended June 30, 2026, to 792 units in the three months ended September 30, 2026. The figures are preliminary and unaudited, so they describe commercial activity rather than final revenue. Citius Oncology said revenue is recognized when wholesaler orders are fulfilled, not when prescribing centers place vial orders.

What does demand mean for scale?

The wider commercial footprint is visible in institutional reach. As of October 26, 2026, 54 institutions had ordered LYMPHIR, compared with 44 institutions reported as of August 14, 2026. Prescribing centers ordered 950 vials in the fiscal fourth quarter, versus 926 in the fiscal third quarter, according to Citius Oncology. Management is targeting formulary placement at 100 priority institutions by the end of calendar year 2026, making the 54-institution figure an important progress marker.

Results date points to December

Citius Oncology expects complete fiscal fourth-quarter and fiscal-year 2026 results in December 2026. TradingView lists December 17, 2026, as the next Citius Pharmaceuticals earnings date. That report should show how much of the preliminary shipment growth converted into recognized revenue and whether the institutional expansion continued.

Commercial base expands before results

Citius Pharmaceuticals owns approximately 71 percent of Citius Oncology, which commercializes LYMPHIR, a targeted immunotherapy for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma. The company also said in an October 12, 2026, release that its Nasdaq-listed business was continuing LYMPHIR commercialization while management attended two investor conferences, according to PR Newswire. The December report will provide the next consolidated test of that commercial strategy.